Evaluation of lipid profile and statin therapy in patients with atrial fibrillation: Real-life data from a tertiary hospital

Abdulrahman Naser; Yücel Uzun; Samet Sayılan; Oya Güven; Merve Demireller; Ahmet Ekmekçi

doi:10.19161/etd.1418118

December 9, 2024Ege Tıp DergisiOpen Access

Evaluation of lipid profile and statin therapy in patients with atrial fibrillation: Real-life data from a tertiary hospital

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Dyslipidemia is a modifiable risk factor for AF, but many patients do not receive LDL-C-lowering treatment or meet lipid goals, prompting evaluation of treatment and target attainment in AF.

Structured PICO

P

Population

675 patients with atrial fibrillation (207 paroxysmal, 468 permanent), mean age 71.98 years, 54.5% female, admitted to a cardiology outpatient clinic of a tertiary hospital in Türkiye.

O

Outcome

Prevalence of dyslipidemia, rate of statin use, and attainment of target LDL-C and non-HDL-C levels according to 2021 ESC-CVD prevention guidelines.surrogate

Control of dyslipidemia in patients with atrial fibrillation is severely poor, largely due to physician inertia, highlighting a significant gap in primary and secondary cardiovascular prevention.

Implication

Physician inertia drives poor statin use and LDL-C control in AF; leaves open whether targeted interventions improve adherence.

Abstract

Aim: Dyslipidemia is a modifiable risk factor of atrial fibrillation (AF). However, the majority of patients either do not receive low-density lipoprotein cholesterol (LDL-C) lowering treatment or do not meet their LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) goal. We aimed to search whether patients with AF are being treated for dyslipidemia and/or are at target LDL-C and non-HDL-C levels if treated. Materials and Methods: This cross-sectional analysis includes 725 AF patients and was performed between 20 May 2023 and 25 November 2023, in cardiology outpatient clinics of a tertiary hospital. The demographic and clinical features of the patients were recorded. Systemic coronary risk estimation-2 (SCORE2) and old person version algorithms were used for cardiovascular disease (CVD) risk estimation. Primary prevention (PP) group involved patients with low-to-moderate, high and very high CVD risk without established atherosclerotic cardiovascular disease (ASCVD) and secondary prevention (SP) group was consisted of patients with established ASCVD. Results: The mean age of the participants was 71.98± 9.01 and 54.5% (n=368) of patients were females. 207 (30.7%) of patients were paroxysmal AF, and 468 (69.3%) were permanent AF. Prevalence of dyslipidemia and hypertriglyceridemia were 364 (53.9%) and 248 (36.7%) respectively. 9 (1.3%) and 152 (22.5%) of patients were on fibrate and statin treatment respectively. Mean LDL-C and non-HDL-C were 107.81±35.97 and 135.42±41.19 and their target attainment rates were 62 (9.2%) and 107 (15.9%), respectively. Conclusion: Control of dyslipidemia in patients with atrial fibrillation was severely poor and the most common cause was physician negligence.